Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. (ONCO) on May 22, 2025, covering events occurring on May 16, 2025, and May 20, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cincinnati, Ohio. The filing addresses a new material definitive agreement and significant regulatory compliance issues regarding its Nasdaq listing status.
Key Financial Metrics and Obligations
The filing details a new debt obligation but does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period.
- New Debt: Issued a promissory note to Keystone Capital Partners, LLC with an aggregate principal amount of $294,117.65.
- Original Issue Discount: $44,117.65.
- Interest: The note does not initially bear interest. Late payments incur a charge of 15% per annum.
- Maturity: Due upon the earlier of receipt of sufficient proceeds from an Equity Line of Credit with the Investor or February 16, 2026.
- Subordination: The note is subordinate to existing debt obligations to Veru Inc.
Material Changes and Regulatory Status
The Company faces critical delisting risks due to multiple compliance failures with Nasdaq listing standards:
- Reporting Delays: Received a deficiency notice on May 20, 2025, for failure to timely file the Form 10-Q for the quarter ended March 31, 2025. This follows a prior notice regarding the failure to file the Form 10-K for the fiscal year ended December 31, 2024.
- Minimum Bid Price Violation: The Company failed to maintain the $1.00 minimum bid price requirement. Additionally, the stock traded at $0.10 or less for ten consecutive trading days, triggering potential delisting under Listing Rule 5810(c)(3)(A)(iii).
- Current Status: Trading suspension was stayed pending a hearing before the Nasdaq Hearings Panel scheduled for May 27, 2025. A stay request for the suspension related to reporting delays was submitted on May 1, 2025.
Outlook, Risks, and Management Commentary
Management, represented by Interim CEO and CFO Karina M. Fedasz, stated the Company is working diligently to finalize and file the overdue 10-K and 10-Q reports on or prior to the May 27, 2025 hearing date. However, the filing explicitly states there are no assurances that the Panel will grant a request for continued listing or an extension. If the Company does not obtain a favorable decision, its Common Stock will be subject to delisting from Nasdaq.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel scheduled for May 27, 2025, regarding both the minimum bid price and reporting deficiency issues.
- Confirm the timely filing of the Form 10-K for the year ended December 31, 2024, and the Form 10-Q for the quarter ended March 31, 2025.
- Monitor the Company's ability to raise capital via the Equity Line of Credit to repay the new $294,117.65 note before the February 16, 2026 maturity.
- Review the full terms of the promissory note attached as Exhibit 10.1 for any additional covenants or conversion rights not summarized in the 8-K.